<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02200978</url>
  </required_header>
  <id_info>
    <org_study_id>2010001</org_study_id>
    <nct_id>NCT02200978</nct_id>
  </id_info>
  <brief_title>A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia</brief_title>
  <official_title>A Multicenter and Randomized Prospective Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>South China Children's Leukemia Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>South China Children's Leukemia Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Outcome of acute promyelocytic leukemia (APL) has greatly improved since the introduction of
      all-trans-retinoic acid (ATRA). Treatment with ATRA and anthracycline-based chemotherapy
      (ATRA + chemotherapy) decreases relapses of the disease as well as early hemorrhagic deaths.
      Nowadays patients with APL have an event-free survival (EFS) of up to 80%. However, there
      remains a subset of the patients in whom the disease relapses. Recently, a randomized
      prospective study showed that the addition of ATO to &quot;ATRA + chemotherapy&quot; treatment protocol
      had a significantly higher EFS in patients with APL than those treated with &quot;ATRA +
      chemotherapy&quot; protocol. The patients treated with &quot;ATO + ATRA + chemotherapy&quot; had a five
      years EFS of 89.2%. Moreover, a recent study showed that Indigo naturalis formula (RIF), a
      traditional Chinese medicine with tetraarsenic tetrasulfide (As4S4), indirubin, and
      tanshinone IIA as major active ingredients, yielded synergy in the treatment of a murine APL
      model in vivo and in the induction of APL cell differentiation in vitro . It is about 20
      years since RIF was used to treat ALP in China. Clinical studies showed that this agent was
      effective against APL. Compared to ATO, RIF is relatively inexpensive and can be taken
      orally, resulting in reducing the number of hospital days and the treatment cost. However,
      there is no report comparing treatment outcomes of &quot;ATO + ATRA + chemotherapy&quot; and &quot;RIF +
      ATRA + chemotherapy&quot; protocols in children with APL so far. For this purpose, therefore,
      investigators are going to conduct a multicenter and randomized prospective study in children
      with APL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the safety and efficacy of &quot;ATO/RIF + ATRA + less intensive chemotherapy&quot;
           protocol in children with acute promyelocytic leukemia (APL).

        -  Compare the safety，efficacy and treatment cost of &quot;RIF + ATRA + less intensive
           chemotherapy&quot; with &quot;ATO + ATRA + less intensive chemotherapy&quot; protocol in children with
           APL. Determine if ATO can be substituted by RIF.

      OUTLINE: This is a multicenter and randomized prospective study.

      PROJECTED ACCRUAL: A total of 162 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>event-free survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>hospitalization cost</measure>
    <time_frame>2 years</time_frame>
    <description>The cost mainly includes the fees of hospital bed, drugs, therapies and blood products. Time frame: from the beginning of induction therapy to the end of maintenance treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Childhood Acute Promyelocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>ATO and chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction:
ATRA 25mg/m2 d1-CR ≯42 days; ATO 0.16mg/kg d5-CR ≯42 days; mitoxantrone (MA) 10mg/m2 d3, or 7mg/m2 d2-4 (high risk).
Consolidation 1:
ATRA 25mg/m2 d1-15; MA 10mg/m2 d1-2; Intrathecal injection (IT)：Ara-C 15mg (age &lt; 1 year), or 20 mg (1-3 years), or 30 mg ( &gt; 3 years), dexamethasone 2mg.
Consolidation 2:
ATRA 25mg/m2 d1-15; ATO 0.16mg/kg d1-15; Ara-C 1g/m2 q12h d1-2 (high risk); IT.
Consolidation 3:
ATRA 25mg/m2 d1-15; ATO 0.16mg/kg d1-15; MA 10mg/m2 d1; Ara-C 1g/m2 q12h d1-2 (high risk); IT.
Maintenance:
① ATO 0.16mg/kg.d w1-2; ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. ② ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. Rotation between ① and ② until the end of maintenance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RIF and chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction:
ATRA 25mg/m2 d1-CR ≯42 days; RIF 0.135/kg d5-CR ≯42 days; mitoxantrone (MA) 10mg/m2 d3, or 7mg/m2 d2-4 (high risk).
Consolidation 1:
ATRA 25mg/m2 d1-15; MA 10mg/m2 d1-2; Intrathecal injection (IT)：Ara-C 15mg (age &lt; 1 year), or 20mg (age 1-3 years), or 30mg (age &gt; 3 years), dexamethasone 2mg.
Consolidation 2:
ATRA 25mg/m2 d1-15; RIF 0.135/kg d1-15; Ara-C 1g/m2 q12h d1-2 (high risk); IT.
Consolidation 3:
ATRA 25mg/m2 d1-15; RIF 0.135/kg d1-15; MA 10mg/m2 d1; Ara-C 1g/m2 q12h d1-2 (high risk); IT.
Maintenance:
① RIF 0.135/kg.d w1-2; ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. ② ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. Rotation between ① and ② until the end of maintenance treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATO</intervention_name>
    <description>Given IV</description>
    <arm_group_label>ATO and chemotherapy</arm_group_label>
    <other_name>As2O3</other_name>
    <other_name>arsenic trioxide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RIF</intervention_name>
    <description>Given orally</description>
    <arm_group_label>RIF and chemotherapy</arm_group_label>
    <other_name>Realgar-Indigo naturalis formula</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATRA</intervention_name>
    <description>Given orally</description>
    <arm_group_label>ATO and chemotherapy</arm_group_label>
    <arm_group_label>RIF and chemotherapy</arm_group_label>
    <other_name>all-trans retinoic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone</intervention_name>
    <description>Given IV</description>
    <arm_group_label>ATO and chemotherapy</arm_group_label>
    <arm_group_label>RIF and chemotherapy</arm_group_label>
    <other_name>novantrone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ara-C</intervention_name>
    <description>Given IV</description>
    <arm_group_label>ATO and chemotherapy</arm_group_label>
    <arm_group_label>RIF and chemotherapy</arm_group_label>
    <other_name>cytarabine</other_name>
    <other_name>cytosine arabinoside</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTX</intervention_name>
    <description>Given orally</description>
    <arm_group_label>ATO and chemotherapy</arm_group_label>
    <arm_group_label>RIF and chemotherapy</arm_group_label>
    <other_name>methotrexate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6MP</intervention_name>
    <description>Given orally</description>
    <arm_group_label>ATO and chemotherapy</arm_group_label>
    <arm_group_label>RIF and chemotherapy</arm_group_label>
    <other_name>mercaptopurine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>intrathecal injection</intervention_name>
    <description>Ara-C and dexamethasone</description>
    <arm_group_label>ATO and chemotherapy</arm_group_label>
    <arm_group_label>RIF and chemotherapy</arm_group_label>
    <other_name>IT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients less than 16 years old with newly diagnosed PML-RARa positive acute
             promyelocytic leukemia.

        Exclusion Criteria:

          -  Patients who have coma, convulsion or paralysis due to intracranial hemorrhage or
             central nervous system leukemia at diagnosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xue-Qun Luo, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xue-Qun Luo, professor</last_name>
      <email>L-xuequn@126.com</email>
    </contact>
    <investigator>
      <last_name>Xue-Qun Luo, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, Shi JY, Zheng PZ, Yan H, Liu YF, Chen Y, Shen Y, Wu W, Tang W, Waxman S, De Thé H, Wang ZY, Chen SJ, Chen Z. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35. Epub 2004 Mar 24.</citation>
    <PMID>15044693</PMID>
  </reference>
  <reference>
    <citation>Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM, Li JM, Tang W, Zhao WL, Wu W, Sun HP, Chen QS, Chen B, Zhou GB, Zelent A, Waxman S, Wang ZY, Chen SJ, Chen Z. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3342-7. doi: 10.1073/pnas.0813280106. Epub 2009 Feb 18.</citation>
    <PMID>19225113</PMID>
  </reference>
  <reference>
    <citation>Wang L, Zhou GB, Liu P, Song JH, Liang Y, Yan XJ, Xu F, Wang BS, Mao JH, Shen ZX, Chen SJ, Chen Z. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4826-31. doi: 10.1073/pnas.0712365105. Epub 2008 Mar 14.</citation>
    <PMID>18344322</PMID>
  </reference>
  <reference>
    <citation>Xiang Y, Wang XB, Sun SJ, Guo AX, Wei AH, Cheng YB, Huang SL. [Compound huangdai tablet as induction therapy for 193 patients with acute promyelocytic leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2009 Jul;30(7):440-2. Chinese.</citation>
    <PMID>19954593</PMID>
  </reference>
  <reference>
    <citation>Luo XQ, Ke ZY, Huang LB, Guan XQ, Zhang YC, Zhang XL. Improved outcome for Chinese children with acute promyelocytic leukemia: a comparison of two protocols. Pediatr Blood Cancer. 2009 Sep;53(3):325-8. doi: 10.1002/pbc.22042.</citation>
    <PMID>19422024</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2014</study_first_submitted>
  <study_first_submitted_qc>July 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2014</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Arsenic trioxide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

